Activity-dependent neuroprotector homeobox protein: A candidate protein identified in serum as diagnostic biomarker for Alzheimer's disease

Journal of Proteomics

Volumn 75, Issue 12, 2012, Pages 3617-3629

  Yang, Ming Hui ^a   Yang, Yuan Han ^b   Lu, Chi Yu ^c   Jong, Shiang Bin ^d   Chen, Li Jhen ^d   Lin, Yu Fen ^d   Wu, Shyh Jong ^d   Chu, Pei Yu ^d   Chung, Tze Wen ^a   Tyan, Yu Chang ^d,e  

^a NATIONAL YUNLIN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

ADNP; Alzheimer's disease; Biomarker; Mass spectrometry; Proteomics

Indexed keywords

ACTIN; ACTIVITY DEPENDENT NEUROPROTECTOR HOMEOBOX PROTEIN; ALPHA 1 ANTITRYPSIN; ANTITHROMBIN III; APOLIPOPROTEIN A4; HOMEODOMAIN PROTEIN; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84862209675     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.04.017     Document Type: Article

References (58)

1. Irizarry M.C., Hyman B.T. Alzheimer disease therapeutics. J Neuropathol Exp Neurol 2001, 60:923-928.
2. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613.
3. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and National Institute on Aging Working Group Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease. Neurobiol Aging 1998, 19:109-116.
4. Patel S., Shah R.J., Coleman P., Sabbagh M. Potential peripheral biomarkers for the diagnosis of Alzheimer's disease. Int J Alzheimers Dis 2011, 9. Article ID 572495, pages.
5. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Figurski M., Coart E., Blennow K., et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011, 121:597-609.
6. Wang J., Eslinger P.J., Doty R.L., Zimmerman E.K., Grunfeld R., Sun X., et al. Olfactory deficit detected by fMRI in early Alzheimer's disease. Brain Res 2010, 1357:184-194.
7. Thambisetty M., Lovestone S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med 2010, 4:65-79.
8. Shi M., Sui Y.T., Peskind E.R., Li G., Hwang H.J., Devic I., et al. Salivary tau species are potential biomarkers of Alzheimer disease. J Alzheimers Dis 2011, 27:299-305.
9. Zabel M., Schrag M., Mueller C., Zhou W., Crofton A., Petersen F., et al. Assessing candidate serum biomarkers for Alzheimer's disease: a longitudinal study. J Alzheimers Dis 2012, 29:1-11. 10.3233/JAD-2012-112012.
10. Mueller C., Zhou W., VanMeter A., Heiby M., Magaki S., Ross M.M., et al. The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease. J Alzheimers Dis 2010, 19:1081-1091.
11. O'Bryant S.E., Xiao G., Barber R., Reisch J., Hall J., Cullum C.M., et al. A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord 2011, 32:55-62.
12. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129:3042-3050.
13. Zilka N., Korenova M., Kovacech B., Novak M. CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy. Acta Neuropathol 2011, 119:679-687.
14. Ewers M., Mielke M.M., Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol 2010, 45:75-79.
15. Fountoulakis M., Juranville J.F., Jiang L., Avila D., Röder D., Jakob P., et al. Depletion of the high-abundance plasma proteins. Amino Acids 2004, 27:249-259.
16. Nagele E., Han M., DeMarshall C., Belinka B., Nagele R. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One 2011, 6:e23112.
17. Yang M.H., Tyan Y.C., Jong S.B., Huang Y.F., Liao P.C., Wang M.C. Identification of human hepatocellular carcinoma-related proteins by proteomic approaches. Anal Bioanal Chem 2007, 388:637-643.
18. Tyan Y.C., Wu H.Y., Su W.C., Chen P.W., Liao P.C. Proteomic analysis of human pleural effusion. Proteomics 2005, 5:1062-1074.
19. Teunissen C.E., Vente J.D., Steinbusch H.W.M., Bruijn C.D. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 2002, 23:485-508.
20. Macher J.P., Crocq M.A. Dialogues in clinical neuroscience 2000, Les Laboratoires Servier, Neuilly-sur-Seine.
21. Craig-Schapiro R., Fagan A.M., Holtzman D.M. Biomarkers of Alzheimer's disease. Neurobiol Dis 2009, 35:128-140.
22. Liao P.C., Yu L., Kuo C.C., Lin C.J., Kuo Y.M. Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease. Proteomics Clin Appl 2007, 1:506-512.
23. Schneider P., Hampel H., Buerger K. Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther 2009, 15:358-374.
24. Shi M., Caudle W.M., Zhang J. Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol Dis 2009, 35:157-164.
25. Thambisetty M., Hye A., Foy C., Daly E., Glover A., Cooper A., et al. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol 2008, 255:1712-1720.
26. Montanelli A., Mainardi E., Pini L., Corda L., Grassi V. Alpha-1-antitrypsin deficiency and nephropathy. Nephron 2002, 90:114-115.
27. Lisowska-Myjak B. AAT as a diagnostic tool. Clin Chim Acta 2005, 352:1-13.
28. Gollin P.A., Kalaria R.N., Eikelenboom P., Rozemuller A., Perry G. Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer's disease. Neuroreport 1992, 3:201-203.
29. 1-antitrypsin as a heme oxygenase-1 suppressor on Alzheimer plasma. Neurobiol Dis 2006, 20:89-100.
30. Soreghan B.A., Lu B.W., Thomas S.N., Duff K., Rakhmatulin E.A., Nikolskaya T., et al. Using proteomics and network analysis to elucidate the consequences of synaptic protein oxidation in a PS1 + AbetaPP mouse model of Alzheimer's disease. J Alzheimers Dis 2005, 8:227-241.
31. Sultana R., Boyd-Kimball D., Poon H.F., Cai J., Pierce W.M., Klein J.B., et al. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 2006, 27:1564-1576.
32. Cohen R.D., Castellani L.W., Qiao J.H., Van Lenten B.J., Lusis A.J., Reue K. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest 1997, 99:1906-1916.
33. Duverger N., Tremp G., Caillaud J.M., Emmanuel F., Castro G., Fruchart J.C., et al. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 1996, 273:966-968.
34. Császára A., Kálmánb J., Szalaic C., Jankab Z., Romicsa L. Association of the apolipoprotein A-IV codon 360 mutation in patients with Alzheimer's disease. Neurosci Lett 1997, 230:151-154.
35. Qin X., Swertfeger D.K., Zheng S., Hui D.Y., Tso P. Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol 1998, 274:H1836-H1840.
36. Wang H.K., Fung H.C., Hsu W.C., Wu Y.R., Lin J.C., Ro L.S., et al. Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer's disease and vascular dementia. J Neural Transm 2006, 113:1499-1509.
37. Hu Y., Hosseini A., Kauwe J.S.K., Gross J., Cairns N.J., Goate A.M., et al. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics Clin Appl 2007, 1:1373-1384.
38. Kalaria R., Golde T., Kroon S.N., Perry G. Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease. Am J Pathol 1993, 143:886-893.
39. Roy S., Josephson S.A., Fridlyand J., Karch J., Kadoch C., Karrim J., et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol 2008, 26:96-105.
40. Deschepper C.F., Bigornia V., Berens M.E., Lapointe M.C. Production of thrombin and antithrombin III by brain and astroglial cell cultures. Brain Res Mol Brain Res 1991, 11:355-358.
41. Piñeiro M., Andrés M., Iturralde M., Carmona S., Hirvonen J., Pyörälä S., et al. ITIH4 (Inter-Alpha-Trypsin Inhibitor Heavy Chain 4) is a new acute-phase protein isolated from cattle during experimental infection. Infect Immun 2004, 72:3777-3782.
42. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007, 117:746-756.
43. Diamandis E.P. Peptidomics for cancer diagnosis: present and future. J Proteome Res 2006, 5:2079-2082.
44. Piñeiro M., Alava M.A., González-Ramón N., Osada J., Lasierra P., Larrad L., et al. ITIH4 serum concentration increases during acute-phase processes in human patients and up-regulated by interleukin-6 in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun 1999, 263:224-229.
45. Wang Z., Yip C., Ying Y., Wang J., Meng X.Y., Lomas L., et al. Mass spectrometric analysis of protein markers for ovarian cancer. Clin Chem 2004, 50:939-1942.
46. Songa F., Poljak A., Smythec G.A., Sachdev P. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev 2009, 61:69-80.
47. Wilkemeyer M.F., Chen S.Y., Menkari C.E., Brenneman D.E., Sulik K.K., Charness M.E. Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc Natl Acad Sci USA 2003, 100:8543-8548.
48. Yenjerla M., LaPointe N.E., Lopus M., Cox C., Jordan M.A., Feinstein S.C., et al. The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules. J Alzheimers Dis 2010, 19:1377-1386.
49. Zemlyak I., Furman S., Brenneman D.E., Gozes I. A Novel peptide prevents death in enriched neuronal cultures. Regul Pept 2000, 96:39-43.
50. Matsuoka Y., Jouroukhin Y., Gray A.J., Ma L., Hirata-Fukae C., Li H.F., et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of alzheimer's disease. J Pharmacol Exp Ther 2008, 325:146-153.
51. Gozes I., Zaltzman R., Hauser J., Brenneman D.E., Shohami E., Hill J.M. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr Alzheimer Res 2005, 2:149-153.
52. Vulih-Shultzman I., Pinhasov A., Mandel S., Grigoriadis N., Touloumi O., Pittel Z., et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 2007, 323:438-449.
53. Fernandez-Montesinos R., Torres M., Baglietto-Vargas D., Gutierrez A., Gozes I., Vitorica J., et al. Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J Mol Neurosci 2010, 41:114-120.
54. Patocka J., Slaninova J., Kunesova G. Neuroprotective peptides as drug candidates against Alzheimer's disease. J Appl Biomed 2005, 3:67-73.
55. Gozes I., Divinski I., Piltzer I. NAP and D-SAL: neuroprotection against the β amyloid peptide (1-42). BMC Neurosci 2008, 9:1-5.
56. O'Donovan C., Martin M., Gattiker A., Gasteiger E., Bairoch A., Apweiler R. High-quality protein knowledge resource: SWISS-PROT and TrEMBL. Brief Bioinform 2002, 3:275-284.
57. Pandey A., Podtelejnikov A.V., Blagoev B., Bustelo X.R., Mann M., Lodish H.F. Analysis of receptor signaling pathways by mass spectrometry: identification of vav-2 as a substrate of the epidermal and platelet-derived growth factor receptors. Proc Natl Acad Sci USA 2000, 7:179-184.
58. Gasteiger E., Gattiker A., Hoogland C., Ivanyi I., Appel R.D., Bairoch A. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res 2003, 31:3784-3788.